Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

November 2020 in “ bioRxiv (Cold Spring Harbor Laboratory) ”

Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, John McCoy

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on medrxiv.org →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men

49 citations , January 2021 in “Journal of The European Academy of Dermatology and Venereology”

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

36 citations , November 2020 in “Journal of The European Academy of Dermatology and Venereology”

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

Women with high androgen levels may have more severe COVID-19 symptoms.

An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

research An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

6 citations , October 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

Early treatment improved COVID-19 outcomes, and spironolactone helped reduce risks in females with high androgen levels.

research Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective

34 citations , September 2020 in “BMC Endocrine Disorders”

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

research Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

36 citations , July 2020 in “Frontiers in Medicine”

Spironolactone might help protect against severe lung problems in COVID-19 patients.

A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

research A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

134 citations , April 2020 in “Journal of Cosmetic Dermatology”

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

research What Does Androgenetic Alopecia Have to Do with COVID-19? An Insight into a Potential New Therapy

47 citations , April 2020 in “Dermatologic Therapy”

Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.